Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants

Table 5

List of some COVID-19 vaccines under phase-3 clinical trials.

Vaccine name and developer	Country	Type	Total number of trials	Number of countries approved for use
COVAXIN-Bharat Biotech	India	Inactivated	16	14
Coronavac-Sinovac	China	Inactivated	42	56
Sputnik Light—Gamaleya	Russia	Viral vector—nonreplicating	7	26
Oxford-AstraZeneca; (Vaxzevria)	United Kingdom–Sweeden	Viral vector—nonreplicating	73	149
Serum Institute of India; Covishield (Oxford/ AstraZeneca formulation)	India	Viral vector—nonreplicating	6	49
Sanofi/GSK; VidPrevtyn beta	United States–Germany	Protein subunit	3	30
Novavax	Australia	Protein subunit	22	40
Recombinant COVID-19 Vaccine National Vaccine and Serum Institute	China	Protein subunit	3	1
Moderna mRNA-1273.214	United States of America	RNA	5	38
Pfizer/BioNTech Comirnaty (BNT162b2)		RNA	100	149